MiCo BioMed (Sung-woo Kim, CEO) has successfully participated in MEDICA 2018, the largest medical equipment exhibition in the world.

'MEDICA' is the world's largest medical device exhibition. It is so-called Mecca of the medical devicemanufacturing companies and is celebrating its 50thexhibition with more than 5300 companies from 66 countries. 70% of the total number of visitors, which is about 130,000, are foreign visitors.

MiCo BioMed is gradually accumulating global recognition and gaining trust in the industry. MikoBioMedhas attended the exhibition for the third time this year.

In particular, MiCo BioMed introduced the main products in biochemistry and molecular diagnostics, and achieved remarkable sales record of $ 600,000 along with meetings with 145 companies.

First, in the biochemistry sector, discussions on contracts with various companies for Veri-Q non-diagnostic products were conducted in depth.

In the biochemistry sector, meetings with 70 companies were conducted. European companies showed the highest interest on our product and accounted for 47% of the total Throughout a number of discussion with various companies from all over the world, we plan to secure and expand the European and the global market.

In the molecular diagnostics sector, Veri-Q PCR 316 product was introduced and additional sales contracts with new Brazil JVC and Indian JVC are in progress. With the agreement for molecular diagnostics, it is expected to generate additional sales of 5bn KRW in 2019. About 40% of the companies that consulted in the molecular diagnostics sector are from Europe, followed by Asia, Middle East and Africa.

There was a conference meeting on proposals for development of government projects and government bids from specific countries.

"It is a remarkable accomplishment that we were able to close 600k USD deal and once again confirmed the competitiveness the company from the renowned exhibition such as Medica German“ said  Sung-woo Kim, CEO of MiCo BioMed.

“Especially the high interest from European countries, which are global core in the Medicare field, is an obvious proof of technical excellence of MiCo BioMed  and the company will accelerate its efforts in overseas markets” added.